LIfT BioSciences Welcomes Immunotherapy Veteran Mark Exley as New CSO
Mark Exley joins LIfT BioSciences as CSO to drive next-gen solid tumour immunotherapy.
.webp&w=1920&q=75&dpl=dpl_DvHKTkTrxtw9jHK6MpkEndZCmmr3)
LIfT BioSciences has announced the appointment of Dr. Mark A. Exley as Chief Scientific Officer, effective April 7, 2025. Known for his deep scientific insight and leadership in immuno-oncology, Exley steps into this key role as LIfT readies its pioneering neutrophil-based cell therapy for clinical trials. With over 30 years of experience driving R&D from discovery through late-stage clinical programs, Exley brings a rare blend of academic excellence and biotech know-how to the team.
His resume includes pivotal leadership roles at Imvax Inc. and MiNK Therapeutics, as well as a long-standing advisory presence in immunotherapy innovation. Exley’s appointment marks a significant milestone in LIfT’s journey to transform cancer treatment through its Neutrophil-based Leukocyte Infusion Therapy (N-LIfT) platform—an approach aiming to restore immune function and counter tumour resistance. The company sees this as a turning point in bringing its vision closer to patients in need.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Altro da Pharma News
Tutti gli articoli →
Medicus Pharma presenta all’FDA il protocollo di fase 2b/3 per Teverelix
Fresenius Kabi Riceve una Lettera di Richiamo dalla FDA dopo Fallimenti nelle Indagini sul Processo Asettico presso lo Stabilimento di Melrose Park
Discussion